Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors.

Autor: Slack, RJ¹, Russell, LJ¹, Hall, DA¹, Luttmann, MA², Ford, AJ¹, Saunders, KA¹, Hodgson, ST³, Connor, HE¹, Browning, C¹, Clark, KL¹, Slack, R J⁴ (AUTHOR), Russell, L J (AUTHOR), Hall, D A (AUTHOR), Luttmann, M A (AUTHOR), Ford, A J (AUTHOR), Saunders, K A (AUTHOR), Hodgson, S T (AUTHOR), Connor, H E (AUTHOR), Clark, K L (AUTHOR)

Publikováno v: British Journal of Pharmacology. Nov2011, Vol. 164 Issue 6, p1627-1641. 15p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).

Autor: Aslanis V; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark. v.aslanis@gmail.com., Abd-Elaziz K; QPS Netherlands BV, Groningen, The Netherlands.; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands., Slack RJ; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Brinch A; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Gravelle L; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Morley W; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Phung; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Herman K; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Holyer I; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Poulsen KK; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Dogterom P; QPS Netherlands BV, Groningen, The Netherlands., Tantawi S; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Zetterberg FR; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Jacoby B; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Schambye H; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark., Lindmark B; Galecto Biotech AB, Ole Maaløes Vej 3, DK-2200, Copenhagen, Denmark.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Nov; Vol. 94 (5), pp. 707-720. Date of Electronic Publication: 2024 Aug 21.

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α v β 6 Integrin Inhibitors.

Autor: Procopiou PA; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Barrett J; Discovery Drug Metabolism & Pharmacokinetics, In Vitro In Vivo Translation, Stevenage SG1 2NY, United Kingdom., Crawford MHJ; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Hatley RJD; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Hancock AP; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Pritchard JM; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Rowedder JE; Translational Biology, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom., Copley RCB; Medicine Development & Supply, Drug Substance Development, Materials Science, Stevenage SG1 2NY, United Kingdom., Slack RJ; Translational Biology, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom., Sollis SL; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Thorp LR; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Lippa RA; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Macdonald SJF; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom., Barrett TN; Medicinal Science & Technology, Medicine Design, Stevenage SG1 2NY, United Kingdom.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Oct 10; Vol. 67 (19), pp. 17497-17519. Date of Electronic Publication: 2024 Sep 13.

The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.

Autor: Comeglio P; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy., Guarnieri G; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Filippi S; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy., Cellai I; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy., Acciai G; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy., Holyer I; Galecto Biotech AB, Copenhagen, Denmark., Zetterberg F; Galecto Biotech AB, Copenhagen, Denmark., Leffler H; Galecto Biotech AB, Copenhagen, Denmark., Kahl-Knutson B; Department of Laboratory Medicine, Lund University, Lund, Sweden., Sarchielli E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Morelli A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Maggi M; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.; Interuniversity Consortium 'Istituto Nazionale Biostrutture e Biosistemi' (INBB), Rome, Italy., Slack RJ; Galecto Biotech AB, Copenhagen, Denmark., Vignozzi L; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.; Interuniversity Consortium 'Istituto Nazionale Biostrutture e Biosistemi' (INBB), Rome, Italy.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2024 Jul 31; Vol. 15, pp. 1430109. Date of Electronic Publication: 2024 Jul 31 (Print Publication: 2024).